Awarded first place in the prestigious Deep Tech startup competition at Foro Transfiere, Spain’s leading R&D and Knowledge Transfer forum. This top honor recognizes the company’s disruptive technological potential and its excellence in transferring high-impact scientific research to the global market.

Selected as a finalist in the RETECH Innovation Forum, a key event within the "Redes de Emprendimiento Digital" national framework. This recognition highlights the project’s strategic value in the digital transformation of the healthcare sector through the integration of advanced data and AI solutions.

Named a finalist in AstraZeneca’s flagship acceleration program, "ACCIÓN," in collaboration with the regional Health Cluster. This selection underscores the company’s clinical relevance and its potential to establish strategic partnerships with the pharmaceutical industry to improve cancer patient outcomes.

A prestigious national recognition by Banco Santander that identifies the most promising high-growth companies in Spain. As a Top 10 Scaleup, the company was selected for its innovative business model, scalability, and potential to lead the digital transformation within the Spanish entrepreneurial ecosystem.

Selected from over 1,200 candidates across 84 countries, the company was named one of the Top 10 finalists in the Valencia Digital Summit (VDS) international competition. This recognition highlights the project’s disruptive nature and its ability to address global challenges through advanced technology and scientific innovation.

National recognition identifying high-potential innovative companies in Spain. As a finalist, the company was selected to represent Spain in the global entrepreneurship stages, highlighting its business scalability and technological impact.

A prestigious international challenge organized by Santander and Philips to find disruptive solutions for healthy aging. The company received an Honorary Mention for its advanced liquid biopsy and AI platform, recognized among 500 participants from 11 countries.

Selected by Emprendedores magazine as one of the 50 most innovative startups in Spain for 2024. This prestigious annual list recognizes companies with the highest disruptive potential, highlighting our advanced AI and genomic sequencing platform as a benchmark in the Spanish deep-tech and healthcare landscape.

Recognized by the Association of Science and Technology Parks of Spain (APTE) as one of the 100 best startups of 2024. This selection highlights the company’s high degree of innovation and its impact within the national technological ecosystem, featuring Altum Sequencing as a leader in scientific excellence and deep-tech development.

Awarded for the Best Business Initiative by the Leganés Business Union (UNELE) during the XIII edition of the City of Leganés Business Awards. This recognition celebrates the company’s technological excellence and its strategic contribution to the local and regional innovation ecosystem as a leading deep-tech firm.

Selected as a finalist in the "Hematology Challenge" organized by AstraZeneca and Kunsen, an initiative dedicated to finding innovative solutions for clinical management in hematology. The company was recognized for its advanced software and genomic approach, aimed at optimizing diagnosis and monitoring for patients with blood cancers.

Recognized as a finalist in the Scaleup Pitch Competition at Al-Andalus Innovation Venture 2024. The company was selected for its high growth potential and disruptive liquid biopsy technology, ClonSite, which enables the detection of one tumor cell among a million healthy cells to prevent cancer relapses.

Selected as a finalist in the Health Vertical at South Summit Madrid, one of the world's leading startup conferences. Chosen from thousands of global applicants, this recognition highlights the company's excellence in biotechnology and its role as a key innovator in the future of healthcare and precision medicine.

Finalist in the MedTech World Pitch competition during the Health Revolution Congress in Barcelona. The jury recognized the company's advanced genomic sequencing kits and AI-driven diagnostic platform for their ability to significantly reduce healthcare costs and improve patient survival rates in oncology.